High-tech meds can cost from €1,000 to €10,000 per patient per month, and total expenditure under the High Tech Medicines Scheme now exceeds €1 billion per year. At that scale, holding even 1 extra week of national stock would tie up close to €20 million in public funds. From a public finance perspective, a just-in-time supply model is the only way to have budgetary control while still giving access to these drugs at all.
The cost of some high-tech medicines is such that, for many patients, the public expenditure on these drugs alone will exceed their total lifetime tax contributions. That is not a criticism of patients but a reflection of the very real scale of modern pharma costs and the degree of collective subsidy involved. Cost control, use monitoring, and fair allocation are essential.
Many of these meds require a strict cold chain, which means big refrigerated storage capacity. Expecting community pharmacies to hold buffer stock would mean costly infrastructure upgrades and introduce additional safety risks. Also, many high-tech medicines have short shelf lives, and patients may stop treatment unexpectedly due to side effects, lack of benefit, or clinical reassessment. Unused medicines cannot be returned and some are patient-specific (for example weight-based dosing or rare indications), so stockpiling would inevitably lead to huge waste.
For many biologics and monoclonal antibodies, global supply is tight for reasons beyond national control. Once a unit is allocated to a named patient, it is effectively removed from the national pool, even if it has not yet been dispensed. Allowing early allocation for some patients would mean other (possibly sicker!) patients could go without. So the system must allocate meds as close as possible to the time of clinical need even when this feels frustrating.
This is why understandable attempts to order early are blocked. From an individual's perspective, a small buffer seems sensible and reduces anxiety, especially around Christmas/bank holidays or when there are supply problems. From a whole system perspective, if even a small minority of people did this the supply chain would become unworkable and inequitable. The rules are blunt and not well explained, and the stress created is real, but the underlying logic is about fairness and sustainability.
If the HSE abandoned just-in-time controls and allowed routine buffer stock it would inevitably (and correctly) face criticism for tying up tens of millions of euro in unused or expired medicines and for disadvantaging vulnerable patients.